Among the potential metabolic targets in NAFLD, fibroblast growth factor 21 (FGF21) is a systemically circulating and liver-derived hormone achieving organ specificity by the tissue distribution of the FGF receptor and its co-receptor β-Klotho, which is mainly expressed in hepatic and adipose tissue [21,22]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.